Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Clinical Trial Data
100%
Recurrent Nasopharyngeal Carcinoma
100%
Standard of Care
37%
Progression-free Survival
25%
Chemotherapy
25%
Clinical Activity
25%
Treatment Options
12%
Clinical Trials
12%
Monotherapy
12%
Tumor Subtype
12%
Poor Prognosis
12%
Survival Benefit
12%
Previously Treated
12%
Head-and-neck Cancer
12%
Efficacy Outcomes
12%
Receptor 1
12%
Conventional Chemotherapy
12%
Chemotherapy Alone
12%
Systemic Therapy
12%
Randomized Clinical Trial
12%
Tolerability
12%
Western Hemisphere
12%
Anti-PD-1 Therapy
12%
Unmet Medical Need
12%
Ongoing Clinical Trials
12%
First-line Chemotherapy
12%
Advanced Tumor
12%
Therapy Regimen
12%
Recurrent or Metastatic
12%
Nasopharyngeal
12%
Chemoimmunotherapy
12%
First-line Regimen
12%
Line Standard
12%
Gemcitabine Plus Cisplatin
12%
Cell Death Receptors
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Nasopharynx Carcinoma
100%
Chemotherapy
50%
Progression Free Survival
25%
Neoplasm
12%
Monotherapy
12%
Head and Neck Cancer
12%
Immunotherapy
12%
Cisplatin
12%
Randomized Clinical Trial
12%
Tolerability
12%
Gemcitabine
12%
Death Receptor
12%
First-Line Chemotherapy
12%
Diseases
12%